This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Jun 1;23(16):3868-9; author reply 3869-70.

doi: 10.1200/JCO.2005.05.203.

It is not time to stop progesterone receptor testing in breast cancer

R Colomer, M Beltran, J Dorcas, H Cortes-Funes, J Hornedo, V Valentin, C Vargas, C Mendiola, E Ciruelos

PMID: 15923595
DOI: 10.1200/JCO.2005.05.203

Comment

It is not time to stop progesterone receptor testing in breast cancer

R Colomer et al. J Clin Oncol. 2005.

. 2005 Jun 1;23(16):3868-9; author reply 3869-70.

doi: 10.1200/JCO.2005.05.203.

Authors

R Colomer, M Beltran, J Dorcas, H Cortes-Funes, J Hornedo, V Valentin, C Vargas, C Mendiola, E Ciruelos

PMID: 15923595
DOI: 10.1200/JCO.2005.05.203

No abstract available

PubMed Disclaimer

Comment on

Time to stop progesterone receptor testing in breast cancer management.
Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Olivotto IA, et al. J Clin Oncol. 2004 May 1;22(9):1769-70. doi: 10.1200/JCO.2004.99.251. J Clin Oncol. 2004. PMID: 15118010 No abstract available.

Similar articles

Time to stop progesterone receptor testing in breast cancer management.
Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Olivotto IA, et al. J Clin Oncol. 2004 May 1;22(9):1769-70. doi: 10.1200/JCO.2004.99.251. J Clin Oncol. 2004. PMID: 15118010 No abstract available.
Progesterone receptor testing: not the right time to be buried.
Colozza M, Larsimont D, Piccart MJ. Colozza M, et al. J Clin Oncol. 2005 Jun 1;23(16):3867-8; author reply 3869-70. doi: 10.1200/JCO.2005.05.167. J Clin Oncol. 2005. PMID: 15923594 No abstract available.
Time for reappraisal of progesterone-receptor testing in breast cancer management.
MacGrogan G, de Mascarel I, Sierankowski G, Mauriac L, Debled M, Durand M, De Lara CT, Avril A, Picot V, Mathoulin-Pélissier S. MacGrogan G, et al. J Clin Oncol. 2005 Apr 20;23(12):2870-1; author reply 2871. doi: 10.1200/JCO.2005.05.241. J Clin Oncol. 2005. PMID: 15838009 No abstract available.
Individualizing therapeutic decision making in early-stage breast cancer.
Oestreicher P. Oestreicher P. ONS Connect. 2007;22(8 Suppl):41-2. ONS Connect. 2007. PMID: 17824559 Review. No abstract available.
[Prognostic and predictive factors in breast cancer].
Bozhok AA, Semiglazov VF, Semiglazov VV, Arzumanov AS, Klettsel' AE. Bozhok AA, et al. Vopr Onkol. 2005;51(4):434-43. Vopr Onkol. 2005. PMID: 16308974 Review. Russian.

See all similar articles

Cited by

Trans-(-)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?
Rattanaburee T, Tanawattanasuntorn T, Thongpanchang T, Tipmanee V, Graidist P. Rattanaburee T, et al. Molecules. 2021 Jul 27;26(15):4537. doi: 10.3390/molecules26154537. Molecules. 2021. PMID: 34361688 Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Steenbruggen TG, et al. Drugs. 2017 Aug;77(12):1313-1336. doi: 10.1007/s40265-017-0774-5. Drugs. 2017. PMID: 28616845 Review.
A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.
Kornaga EN, Klimowicz AC, Guggisberg N, Ogilvie T, Morris DG, Webster M, Magliocco AM. Kornaga EN, et al. Mod Pathol. 2016 Aug;29(8):799-809. doi: 10.1038/modpathol.2016.74. Epub 2016 Apr 29. Mod Pathol. 2016. PMID: 27125355
Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y, Ding X, Xu B, Ma F, Yuan P, Wang J, Zhang P, Li Q, Luo Y. Fan Y, et al. Medicine (Baltimore). 2015 Nov;94(46):e2066. doi: 10.1097/MD.0000000000002066. Medicine (Baltimore). 2015. PMID: 26579819 Free PMC article.
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
Dai X, Xiang L, Li T, Bai Z. Dai X, et al. J Cancer. 2016 Jun 23;7(10):1281-94. doi: 10.7150/jca.13141. eCollection 2016. J Cancer. 2016. PMID: 27390604 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program